Atrium Therapeutics to Present Nonclinical Data on ATR 1072
The company will present data at AHA Scientific Sessions 2026 showing its investigational drug ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 syndrome mouse model, str…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The company will present data at AHA Scientific Sessions 2026 showing its investigational drug ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 syndrome mouse model, str…
The USArmy Corps of Engineers issued a Public Notice for a critical mineral project road while the Governor requested federal assistance. The permit has emergency processing status…
The FDA granted accelerated approval to Voceryq for treating adults with recurrent respiratory papillomatosis, marking the first plasmid DNA-based immunotherapy for this indication…
The company filed an exhibit to formally amend and restate its Certificate of Designation.
Annovis Bio received a Notice from the NYSE indicating it is out of compliance with continued listing standards due to a market cap and equity imbalance. The company will submit a …
The company received a notice of non-compliance regarding market cap and stockholders' equity but intends to submit a business plan to maintain its listing.
NeoVolta Inc. filed its Third Amended and Restated Bylaws with the SEC, establishing internal governance rules for the Nevada corporation. This regulatory filing is a standard admi…
Deloitte commented on a Form 8-K dated Oct 30, 2026, agreeing with certain statements but having no basis to comment on others, which requires careful review by investors.
Moleculin completes dosing in Phase 2/3 MIRACLE trial evaluating Annamycin. The company is on track to report comprehensive Part A data in Q1 2027, which is expected to support dos…
Oxford Square Capital Corp filed an exhibit amending its Fifth Amended and Restated Bylaws, effective October 28, 2026.
Acumen Pharmaceuticals reported that sabirnetug failed to meet its primary cognitive endpoint in a Phase 2 trial for Alzheimer's disease, leading the company to halt development of…
The Federal Reserve Board has approved an application by The Bank of Nova Scotia, effective immediately.
Dine Brands adopted a rights agreement to protect stockholders' interests following market activity. The measure, set to expire October 2027, aims to prevent hostile takeovers and …
Amass Brands amended its bylaws to lower the quorum threshold for stockholder meetings from a majority to one-third of voting power, effective Oct. 29, 2026. Shareholders absent a …
Verisk Analytics, Inc. has issued a statement following a Delaware Supreme Court order affirming a lower court decision, though the AccuLynx transaction is still subject to closing…
Iovance reported a 24.6% objective response rate in non-squamous mNSCLC, enabling a planned sBLA in 2027 and initiation of a precision TIL strategy for evaluating specific biomarke…
OFA Group approved an amendment to its Series A Convertible Preferred Shares to reduce the Floor Price to $0.20 per share, effective October 22, 2026, with consent from required Ch…
Twin Disc filed Exhibits of its Restated Bylaws. The restatement establishes rules for shareholder meetings and corporate governance. This filing sets the framework for corporate a…
TEN Holdings adjourned its 2026 Annual Meeting to secure votes for electing directors and appointing an auditor. The virtual meeting is reconvened for November 12, 2026.
CervoMed announced peer-reviewed studies supporting neflamapimod as a DLB treatment. Positive trial biomarkers reinforce the drug's mechanism and rationalize further clinical devel…